期刊
MOLECULAR PHARMACOLOGY
卷 74, 期 5, 页码 1215-1222出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.108.049114
关键词
-
资金
- National Institute on Deafness and Other Communication Disorders [Z01-DC-00016]
- National Institutes of Health Intramural Research Program for Center for Cancer Research
- National Cancer Institute
- National Institutes of Health-approved Cooperative Research and Development Agreement with Millennium Pharmaceuticals
Nuclear factor-kappa B (NF-kappa B) influences the initiation, progression, and maintenance of diverse cancer types. Despite current therapeutic efforts to block hyperactive NF-kappa B in cancer cells, the in vivo effects of a drug upon this complex pathway are unclear. We monitored NF-kappa B activity and a fast-expressing reporter level simultaneously in head and neck squamous carcinoma cells by quantitative live microscopy. The real-time single cell assay revealed the tumor necrosis factor-alpha-induced oscillation of NF-kappa B was echoed by equally dynamic reporter expression rate. Bortezomib is a proteasome inhibitor whose anticancer action is partly mediated through inhibition of NF-kappa B. When administered to preactivated cells, the drug gave rise to distinct inhibition dynamics, with discrete pulses of reporter induction remaining for hours. These findings suggest that, contrary to a simplistic presumption for a pathway blockade, the network dynamics and the intracellular pharmacokinetics of the inhibitor must be critically evaluated in developing strategies for optimal intervention of oncogenic pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据